Author

Mirna Chehade

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

Mirna Chehade  et al.

DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS - DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1-11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS
DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS - DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1-11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS

DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS
DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS

Mirna Chehade  et al.

DUPILUMAB IS EFFECTIVE IN TREATING EOE REGARDLESS OF BASELINE WEIGHT OR BMI: POOLED RESULTS FROM PART A AND PART B OF THE LIBERTY EOE TREET STUDY
DUPILUMAB IS EFFECTIVE IN TREATING EOE REGARDLESS OF BASELINE WEIGHT OR BMI: POOLED RESULTS FROM PART A AND PART B OF THE LIBERTY EOE TREET STUDY

Mirna Chehade  et al.

DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY
DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY

Mirna Chehade  et al.

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PARTS B AND C OF THE RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PARTS B AND C OF THE RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Mirna Chehade  et al.

HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITIS AND/OR DUODENITIS AMONG PATIENTS WITH CHRONIC FUNCTIONAL GASTROINTESTINAL SYMPTOMS
HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITIS AND/OR DUODENITIS AMONG PATIENTS WITH CHRONIC FUNCTIONAL GASTROINTESTINAL SYMPTOMS

Mirna Chehade  et al.

DUPILUMAB NORMALIZES EXPRESSION OF GENES ASSOCIATED WITH TYPE 2 INFLAMMATION IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
DUPILUMAB NORMALIZES EXPRESSION OF GENES ASSOCIATED WITH TYPE 2 INFLAMMATION IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

Mirna Chehade  et al.

THE GENE EXPRESSION SIGNATURE MODULATED BY DUPILUMAB IS HIGHLY CORRELATED WITH EOSINOPHILIC ESOPHAGITIS HISTOLOGICAL SEVERITY
THE GENE EXPRESSION SIGNATURE MODULATED BY DUPILUMAB IS HIGHLY CORRELATED WITH EOSINOPHILIC ESOPHAGITIS HISTOLOGICAL SEVERITY

Mirna Chehade  et al.

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS
SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS

Mirna Chehade  et al.

Item 1 - 10 / 10
1